Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.

Klintman, Marie LU ; Ornbjerg Würtz, Sidse ; Christensen, Ib ; Bræmer Hertel, Pernille ; Fernö, Mårten LU ; Malmberg, Martin ; Mouridsen, Henning ; Cold, Frederik ; Schrohl, Anne-Sofie and Foekens, John , et al. (2010) In Breast Cancer Research and Treatment 121. p.365-371
Abstract
In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy.... (More)
In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer. (Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; and (Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
in
Breast Cancer Research and Treatment
volume
121
pages
365 - 371
publisher
Springer
external identifiers
  • wos:000277906500011
  • pmid:19653096
  • scopus:77953020152
ISSN
1573-7217
DOI
10.1007/s10549-009-0483-1
language
English
LU publication?
yes
id
84ccbdc3-5858-4b6e-ae97-9c45fedb6f1c (old id 1470053)
alternative location
http://www.ncbi.nlm.nih.gov/pubmed/19653096?dopt=Abstract
date added to LUP
2016-04-04 09:35:53
date last changed
2022-01-29 18:37:57
@article{84ccbdc3-5858-4b6e-ae97-9c45fedb6f1c,
  abstract     = {{In a previous study from our laboratory, high tumor levels of tissue inhibitor of metalloproteinases-1 (TIMP-1) have been associated with an adverse response to chemotherapy in metastatic breast cancer suggesting that TIMP-1, which is known to inhibit apoptosis, may be a new predictive marker in this disease. The purpose of this study was to investigate the association between TIMP-1 and objective response to chemotherapy in an independent patient population consisting of patients with metastatic breast cancer from Sweden and Denmark. TIMP-1 was measured using ELISA in 162 primary tumor extracts from patients who later developed metastatic breast cancer and these levels were related to the objective response to first-line chemotherapy. Increasing levels of TIMP-1 were associated with a decreasing probability of response to treatment, reaching borderline significance (OR = 1.59, 95% CI: 0.97-2.62, P = 0.07). This OR is very similar to the result from our previous study. Increasing levels of TIMP-1 were also associated with a shorter disease-free survival and overall survival, however, not statistically significant. The results from the present study support previous data that TIMP-1 is associated with objective response to chemotherapy for metastatic breast cancer.}},
  author       = {{Klintman, Marie and Ornbjerg Würtz, Sidse and Christensen, Ib and Bræmer Hertel, Pernille and Fernö, Mårten and Malmberg, Martin and Mouridsen, Henning and Cold, Frederik and Schrohl, Anne-Sofie and Foekens, John and Malmström, Per and Brünner, Nils}},
  issn         = {{1573-7217}},
  language     = {{eng}},
  pages        = {{365--371}},
  publisher    = {{Springer}},
  series       = {{Breast Cancer Research and Treatment}},
  title        = {{Association between tumor tissue TIMP-1 levels and objective response to first-line chemotherapy in metastatic breast cancer.}},
  url          = {{http://dx.doi.org/10.1007/s10549-009-0483-1}},
  doi          = {{10.1007/s10549-009-0483-1}},
  volume       = {{121}},
  year         = {{2010}},
}